FIGURE 1.

(A) Myelofibrosis‐free survival (MFS) among 471 JAK2V617F mutated 2016‐WHO essential thrombocythemia (ET) patients from University of Florence cohort, stratified by their VAF, ≤ 35% vs. >35%; (B) MFS among 7 182 016‐WHO ET patients from University of Florence cohort, fully annotated for driver mutation type and JAK2V617F VAF, stratified by high‐risk (JAK2V617F VAF >35%, CALR type 1/1‐like and MPL) and low‐risk (JAK2V617F VAF ≤35%, CALR type 2/2‐like and TN) for MF progression. (C) External validation of the molecular model in 479 ET patients from Mayo Clinic, USA and (D) 410 from Policlinico Gemelli, Catholic University, Italy [Color figure can be viewed at wileyonlinelibrary.com]